BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed NBIX catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:95ea3cbf1aac02b73dfe@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:NBIX P2 readout (est.): Efficacy\, Safety\, and Tolerability of NBI
 -1065890 Versus Placebo in Adults With Tardive Dyskinesia
DESCRIPTION:Efficacy\, Safety\, and Tolerability of NBI-1065890 Versus Plac
 ebo in Adults With Tardive Dyskinesia\nNCT07365462 | PHASE2 | RECRUITING |
  sponsor: Neurocrine Biosciences\nPrimary completion date (ESTIMATED)\; to
 p-line results usually follow later.\nDate precision: month (shown on the 
 first day)\nTicker NBIX (confidence 0.9)\nSource: https://clinicaltrials.g
 ov/study/NCT07365462\nScheduling/reference data from public records\; date
 s can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07365462
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
